FDA Approves Eli Lilly's Inluriyo for Advanced ER+ Breast Cancer
TL;DR Summary
The FDA has approved Eli Lilly's Inluriyo (imlunestrant), an oral treatment for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer, based on its ability to significantly improve progression-free survival in clinical trials, offering a new oral option for this patient group.
- U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Eli Lilly and Company
- Eli Lilly's oral SERD Inluriyo passes muster with FDA in breast cancer Fierce Pharma
- Eli Lilly wins approval of imlunestrant for breast cancer Seeking Alpha
- Recon: RFK Jr. launches review of mifepristone; FDA approves Lilly’s advanced breast cancer drug Regulatory Affairs Professionals Society | RAPS
- Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease The ASCO Post
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
10 min
vs 11 min read
Condensed
98%
2,087 → 43 words
Want the full story? Read the original article
Read on Eli Lilly and Company